Want to see IMMP full AI Analyst Report?
IMMP Stock Chart & Stats
$2.04
-$0.05(-2.44%)
At close: 4:00 PM EST
$2.04
-$0.05(-2.44%)
Day’s Range― - ―
52-Week Range$0.29 - $3.53
Previous CloseN/A
Volume50.42K
Average Volume (3M)863.74K
Market Cap
$48.61M
Enterprise Value$4.57M
Total Cash (Recent Filing)$99.13M
Total Debt (Recent Filing)$1.21M
Price to Earnings (P/E)―
Beta2.20
Next Earnings
Sep 02, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding147,372,130
10 Day Avg. Volume390,585
30 Day Avg. Volume863,739
Financial Highlights & Ratios
PEG Ratio-0.32
Price to Book (P/B)2.53
Price to Sales (P/S)71.92
P/FCF Ratio-5.84
Enterprise Value/Market Cap0.09
Enterprise Value/Revenue0.58
Enterprise Value/Gross Profit-0.06
Enterprise Value/Ebitda-0.06
Forecast
1Y Price Target
$1.50Price Target Upside-26.47% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.13
Revenue Forecast (FY)$4.09M
Bulls Say, Bears Say
Bulls Say
LAG‑3 Platform LeadershipImmutep’s concentrated expertise in LAG‑3 biology with multiple distinct programs across oncology and autoimmune indications creates a durable platform advantage. A focused scientific moat increases probability of repeatable opt‑ins by partners and multiple value-creation pathways beyond any single asset.
IMP761 Phase I Safety And PDRobust Phase I safety and pharmacodynamic signals for IMP761 validate the company’s agonist approach in autoimmune disease. Clinically meaningful PD and practical dosing cadence de‑risks progression to Phase II, strengthens partner interest, and diversifies long‑term revenue pathways beyond oncology.
Orphan Designation For EftiOrphan Drug Designation confers regulatory incentives and potential market exclusivity for efti in soft tissue sarcoma. This designation materially improves the feasibility of a focused late‑stage program and enhances the asset’s strategic appeal to partners seeking niche oncology opportunities.
Bears Say
Persistent Negative Cash FlowChronic operating and free cash flow deficits are a durable constraint for a clinical‑stage biotech, forcing reliance on partners or capital markets. Ongoing cash burn can limit trial scope, delay development timelines and dilute existing shareholders if recurring financing is required to sustain operations.
Phase III Failure In NSCLC (TACTI‑004)A halted Phase III program represents a material development risk: sunk costs, lost time, and the need to rethink efti’s pivotal strategy. Such failures can undermine partner confidence, necessitate program pivots, and increase uncertainty around future regulatory or commercial prospects for the asset class.
Nasdaq Bid‑price Non‑compliance NoticeA sustained bid‑price deficiency raises structural liquidity and investor‑access risks. Potential delisting or continued noncompliance could reduce U.S. investor participation, complicate future equity raises and partnerships, and materially affect the company’s ability to finance costly clinical development long term.
Immutep News
IMMP FAQ
What was Immutep’s price range in the past 12 months?
Immutep lowest stock price was $0.29 and its highest was $3.53 in the past 12 months.
What is Immutep’s market cap?
Immutep’s market cap is $48.61M.
When is Immutep’s upcoming earnings report date?
Immutep’s upcoming earnings report date is Sep 02, 2026 which is in 64 days.
How were Immutep’s earnings last quarter?
Immutep released its earnings results on Feb 24, 2026. The company reported -$0.217 earnings per share for the quarter, missing the consensus estimate of -$0.197 by -$0.02.
Is Immutep overvalued?
According to Wall Street analysts Immutep’s price is currently Overvalued.
Does Immutep pay dividends?
Immutep does not currently pay dividends.
What is Immutep’s EPS estimate?
Immutep’s EPS estimate is -0.05.
How many shares outstanding does Immutep have?
Immutep has 147,372,130 shares outstanding.
What happened to Immutep’s price movement after its last earnings report?
Immutep reported an EPS of -$0.217 in its last earnings report, missing expectations of -$0.197. Following the earnings report the stock price went down -0.357%.
Which hedge fund is a major shareholder of Immutep?
Currently, no hedge funds are holding shares in IMMP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immutep Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1.50 (-26.47% Downside)
$1.50 (-26.47% Downside)
Hedge Fund Trend
Decreased
By 564.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 3.4%
Last 30 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.07%
12-Months-Change
Fundamentals
Return on Equity
-69.20%
Trailing 12-Months
Asset Growth
-13.05%
Trailing 12-Months
Company Description
Immutep
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
IMMP Stock 12 Month Forecast
Average Price Target
$1.50
▼(-26.47% Downside)
Technical Analysis
Ownership Overview
―
Insiders
0.02% Mutual Funds
0.32% Other Institutional Investors
99.15% Public Companies and
Individual Investors